hogfan's picks

[hogfan2]

$CUR...http://www.thelifesciencesreport.com/pub/co/4857#quote
Neuralstem Inc. is focused on developing and commercializing treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs. The company has developed and maintains a portfolio of patents and patent applications that … read more
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Larry Smith, SmithOnStocks (12/18/14) "Neuralstem Inc. has noted in response to questions that it appears to be seeing encouraging signs in the patients initially treated in the Chinese ischemic stroke trial; however, this is the very early 'dose up' part of the trial. In the U.S., this would be called a Phase 1b trial that treats patients suffering from the disease state as opposed to healthy volunteers."
Jason Napodano, Zacks Small-Cap Research (11/7/14) "The last patient has been treated in Neuralstem Inc.'s Phase 2 amyotrophic lateral sclerosis study, and data are expected during Q1/15. The first patient in the spinal cord injury study has been treated, and we expect continued enrollment of this trial in 2015." -Zacks Small-Cap Research
Jason Napodano, Seeking Alpha (10/15/14) "For the purpose of our financial model, we assume that if Neuralstem Inc.'s NSI-566 works, regardless of the entry criteria for the Phase 1 trial, neurosurgeons will use it in all patients and all areas of injury. . .as for the price of the surgery, we believe $150K is realistic. . .if we apply these data in a detailed epidemiology and pricing model, with 5% U.S. market share, NSI-566 is a potential $500M drug."
Reni Benjamin, H.C. Wainwright & Co. (10/13/14) "Last Thursday, Neuralstem Inc. announced that the first of four chronic spinal cord injury patients in a Phase 1 trial of NSI-566 was recently treated at the University of California, San Diego School of Medicine. . .we view the forward progress of the trial as welcome news for investors; it marks a foray into an indication area with a potentially addressable patient population nearly 10 times that of amyotrophic lateral sclerosis."
Ram Selvaraju, Aegis Capital (10/9/14) "This morning, Neuralstem Inc. announced that the first patient was treated last week in the firm's Phase 1 trial testing NSI-566. . .we are encouraged to see the initiation of this important clinical program, and believe that preclinical evidence of NSI-566 therapeutic efficacy is particularly strong in the context of spinal cord injury."
more comments